A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis

PHASE3CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 4, 2022

Primary Completion Date

July 2, 2024

Study Completion Date

August 22, 2025

Conditions
Eosinophilic Gastroenteritis
Interventions
DRUG

CC-93538

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (25)

5011194

Local Institution - 024, Gifu

670-8560

Local Institution - 022, Himeji-shi

663-8501

Local Institution - 009, Nishinomiya

514-8507

Local Institution - 0025, Tsu

Local Institution - 025, Tsu

982-8502

Local Institution - 023, Sendai

113-8603

Local Institution - 007, Bunkyo-ku

157-8535

Local Institution - 001, Setagaya-ku

010-8543

Local Institution - 010, Akita

036-8545

Local Institution - 017, Hirosaki

734-8551

Local Institution - 015, Hiroshima

890-8520

Local Institution - 018, Kagoshima

802-8561

Local Institution - 020, Kitakyushu

650-0017

Local Institution - 004, Kobe

371-8511

Local Institution - 011, Maebashi

940-2085

Local Institution - 013, Nagaoka

852-8501

Local Institution - 016, Nagasaki

454-8509

Local Institution - 006, Nagoya

467-8602

Local Institution - 021, Nagoya

951-8510

Local Institution - 008, Niigata

545-8586

Local Institution - 002, Osaka

503-8502

Local Institution - 012, Ōgaki

377-8577

Local Institution - 005, Shibukawa

108-8329

Local Institution - 019, Tokyo

990-9585

Local Institution - 003, Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY